Medical Devices

62 tickers in this theme
Ranks this page's recent reports by score.
Koninklijke Philips N.V.
PHG·Healthcare
B ★★★Hold
Current$30.51
Target$34.08
Return+11.7%
Nov 6, 2026

Philips offers exposure to improving medical technology demand and a credible margin recovery at a reasonable normalized valuation, but Respironics liabilities and modest returns on capital constrain its rerating potential.

Score
67
Henry Schein, Inc.
HSIC·Healthcare
A ★★★★Buy
Current$85.31
Target$98.60
Return+15.6%
Nov 6, 2026

Henry Schein offers a healthcare distribution earnings-recovery opportunity supported by share gains, margin expansion, and buybacks, although elevated leverage and modest returns on invested capital constrain its upside.

Score
75
Revvity, Inc.
RVTY·Healthcare
B ★★★Hold
Current$150.83
Target$152.50
Return+1.1%
Nov 6, 2026

Revvity's specialized life-sciences and diagnostics franchises offer improving organic growth and strong cash generation, but elevated valuation multiples and weak reported returns on capital limit near-term upside.

Score
69
Waters Corporation
WAT·Healthcare
B ★★★Hold
Current$453.08
Target$472.50
Return+4.3%
Nov 6, 2026

Waters combines durable laboratory instrumentation, recurring consumables, and expanding diagnostics exposure with meaningful synergy opportunities, but elevated leverage and demanding cash-flow expectations limit its near-term investment appeal.

Score
68
Fresenius Medical Care AG
FMS·Healthcare
A ★★★★Buy
Current$23.66
Target$26.40
Return+11.6%
Nov 6, 2026

Fresenius Medical Care offers durable dialysis demand, strong free cash flow, and buyback-supported earnings recovery at a modest valuation, although reimbursement pressure, weak treatment volumes, and restructuring execution remain significant risks.

Score
77
Grifols, S.A.
GRFS·Healthcare
B ★★★Hold
Current$8.60
Target$10.50
Return+22.1%
Nov 5, 2026

Grifols combines durable plasma-derived medicine demand with improving cash flow and deleveraging potential, but substantial debt, capital intensity, and Chinese albumin weakness constrain its valuation recovery.

Score
69
IDEXX Laboratories, Inc.
IDXX·Healthcare
A ★★★★Buy
Current$698.55
Target$653.60
Return-6.4%
Nov 5, 2026

IDEXX combines a deeply integrated veterinary diagnostics ecosystem with exceptional cash generation and recurring revenue growth, but its substantial valuation premium leaves investors exposed to slower testing demand or earnings growth.

Score
78
Glaukos Corporation
GKOS·Healthcare
B ★★★Hold
Current$237.60
Target$208.45
Return-12.3%
Nov 2, 2026

Glaukos combines accelerating ophthalmic treatment adoption, differentiated clinical technology, and emerging profitability, but its premium valuation leaves limited room for commercialization or earnings disappointments.

Score
70
Merit Medical Systems, Inc.
MMSI·Healthcare
A ★★★★Buy
Current$86.24
Target$102.30
Return+18.6%
Nov 1, 2026

Merit Medical offers durable procedure-driven growth, improving margins, and a discount to historical valuation levels, but competition, acquisition execution, and demanding cash flow expectations remain key risks.

Score
79
West Pharmaceutical Services, Inc.
WST·Healthcare
B ★★★Hold
Current$412.62
Target$388.74
Return-5.8%
Nov 1, 2026

West Pharmaceutical Services benefits from entrenched pharmaceutical containment relationships and rising demand for premium injectable components, but its elevated valuation requires sustained growth and stronger cash conversion.

Score
69
ResMed Inc.
RMD·Healthcare
A ★★★★Buy
Current$229.94
Target$254.10
Return+10.5%
Nov 1, 2026

ResMed combines a durable sleep therapy franchise, recurring mask revenue, and high cash returns with a relatively attractive valuation, although evolving treatment alternatives and operating-margin pressure could constrain future earnings growth.

Score
83
Illumina, Inc.
ILMN·Healthcare
B ★★★Hold
Current$235.99
Target$210.00
Return-11.0%
Nov 1, 2026

Illumina's entrenched sequencing ecosystem and improving cash generation offer long-term growth potential, but demanding valuation, China restrictions and competitive technology risks constrain near-term upside.

Score
67